Cardiovascular Research Team, San Carlo Clinic, Milano, Italy.
Cardiovascular Research Team, San Carlo Clinic, Milano, Italy.
JACC Cardiovasc Interv. 2020 Dec 28;13(24):2840-2849. doi: 10.1016/j.jcin.2020.08.035. Epub 2020 Nov 25.
This study sought to compare the performance of a novel drug-coated balloon (DCB) (Elutax SV, Aachen Resonance, Germany), with an everolimus-eluting stent (EES) (Abbott Vascular, Santa Clara, California) in patients with de novo lesions.
Small vessel coronary artery disease (SVD) represents one of the most attractive fields of application for DCB. To date, several devices have been compared with drug-eluting stents in this setting, with different outcomes.
The PICCOLETO II (Drug Eluting Balloon Efficacy for Small Coronary Vessel Disease Treatment) trial was an international, investigator-driven, multicenter, open-label, prospective randomized controlled trial where patients with de novo SVD lesions were randomized to DCB or EES. Primary study endpoint was in-lesion late lumen loss (LLL) at 6 months (independent core laboratory), with the noninferiority between the 2 arms hypothesized. Secondary endpoints were minimal lumen diameter, percent diameter stenosis at angiographic follow-up, and the occurrence of major adverse cardiac events at 12 months.
Between May 2015 and May 2018, a total of 232 patients were enrolled at 5 centers. After a median of 189 (interquartile range: 160 to 202) days, in-lesion LLL was significantly lower in the DCB group (0.04 vs. 0.17 mm; p = 0.001 for noninferiority; p = 0.03 for superiority). Percent diameter stenosis and minimal lumen diameter were not significantly different. At 12-month clinical follow-up, major adverse cardiac events occurred in 7.5% of the DES group and in 5.6% of the DCB group (p = 0.55). There was a numerically higher incidence of spontaneous myocardial infarction (4.7% vs. 1.9%; p = 0.23) and vessel thrombosis (1.8% vs. 0%; p = 0.15) in the DES arm.
In this multicenter randomized clinical trial in patients with de novo SVD lesions, a new-generation DCB was found superior to EES in terms of LLL as the angiographic pattern and comparable in terms of clinical outcome. (Drug Eluting Balloon Efficacy for Small Coronary Vessel Disease Treatment [PICCOLETO II]; NCT03899818).
本研究旨在比较新型药物涂层球囊(DCB)(德国 Aachen Resonance 的 Elutax SV)与依维莫司洗脱支架(EES)(加利福尼亚州圣克拉拉的 Abbott Vascular)在新发病变患者中的表现。
小血管冠状动脉疾病(SVD)是 DCB 最具吸引力的应用领域之一。迄今为止,已有多种设备在该环境下与药物洗脱支架进行了比较,结果有所不同。
PICCOLETO II (药物涂层球囊治疗小血管病变的疗效)试验是一项国际、研究者驱动的、多中心、开放标签、前瞻性随机对照试验,其中将新发 SVD 病变患者随机分为 DCB 组或 EES 组。主要研究终点为 6 个月时(独立核心实验室)的靶病变内晚期管腔丢失(LLL),假设 2 组之间无差异。次要终点为血管造影随访时的最小管腔直径、狭窄百分比和 12 个月时的主要不良心脏事件。
2015 年 5 月至 2018 年 5 月,共 5 个中心入组 232 例患者。在中位时间 189(四分位距:160 至 202)天后,DCB 组靶病变内 LLL 显著降低(0.04 比 0.17mm;非劣效性 p=0.001;优效性 p=0.03)。狭窄百分比和最小管腔直径无显著差异。在 12 个月的临床随访中,DES 组发生 7.5%的主要不良心脏事件,DCB 组发生 5.6%(p=0.55)。DES 组心肌梗死发生率(4.7%比 1.9%;p=0.23)和血管血栓形成发生率(1.8%比 0%;p=0.15)均高于 DCB 组。
在这项针对新发 SVD 病变患者的多中心随机临床试验中,一种新一代的 DCB 在 LLL 方面优于 EES,表现为血管造影模式,而在临床结果方面相当。(药物涂层球囊治疗小血管病变的疗效[PICCOLETO II];NCT03899818)。